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Abstract: The treatment of the underlying disease process causing multiple sclerosis has 
continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is 
on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). 
The assessment of which disease modifying medication to use as initial therapy has continued to 
remain a combination of science and the art of medicine. Equally important are the assessment 
of treatment failure and the subsequent choice of medication change. This article will present 
scientific information, as well as information about clinical decision making, about these choices, 
with emphasis on the changing role of glatiramer acetate in this process.
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Introduction
Most cases of multiple sclerosis (MS) are currently thought to be caused by an 
  autoimmune process in which activated lymphocytes and other immune cells infiltrate 
the central nervous system (CNS) and cause inflammatory damage to the myelin 
sheath of axons.1 In recent years, it has become apparent that damage to the axons 
and neurons also occurs early in the disease process. In fact, damage to the axons 
and neuronal cell bodies may be a cause of greater permanent disability than myelin 
damage.2
The underlying cause of this immune attack is unknown, but recent evidence 
implicates genetic, infectious and environmental factors in the development of this 
condition.
Many genes have been implicated in the disease process, with most being involved 
in either susceptibility to developing MS or determination of MS severity. No gene 
has been identified that actually causes MS. Many of the genes that have been identi-
fied are related, through uncertain biological mechanisms, to immune cell function or 
inflammatory molecule processes.3
One or more infectious processes may serve as a trigger for the disease. Over the 
years many organisms have been suggested, but recent evidence has implicated the 
Epstein-Barr virus as the triggering organism in most, if not all, MS cases.4,5
Finally, over many years, epidemiological studies have suggested that environ-
mental factors may influence the development of MS. Recent data suggest that higher 
sunlight exposure and/or vitamin D supplementation in childhood may decrease 
the risk of MS, suggesting that this is the environmental factor implicated in the 
  development of MS.6,7 Other recent data have suggested that vitamin D has effects on  Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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immune system function and abnormal genetic loci involved 
in vitamin D effects have been identified in MS patients.8
Current approved MS therapies
No approved treatments were available to control the disease 
process until 1993 when interferon-beta-1b   (Betaseron® 
[Bayer], Betaferon® [Bayer], and recently, Extavia®   [Novartis]) 
became the first approved drug shown to slow the disease 
process. This was followed within a few years by interferon-
beta-1a (Avonex® [Biogen Idec], and, later, glatiramer acetate 
(Copaxone® [Teva]), Rebif® [Merck Serono]).
The complete biochemical mechanism of action of these 
drugs is still unknown. The interferons are large molecules 
that interact with surface receptors on immunocompetent cells 
and stimulate certain internal genetic processes. The resultant 
proteins downregulate immune system function in multiple 
aspects, perhaps most importantly by reducing trafficking of 
activated lymphocytes across the blood–brain barrier (BBB) 
into the CNS. Other proposed effects of interferons on the 
immune system include inhibition of T-cell activation and 
proliferation, apoptosis of autoreactive T-cells, induction of 
autoreactive T-cells, induction of regulatory T-cells, inhibition 
of leukocyte migration across the BBB, cytokine modulation, 
and potential antiviral activity. Furthermore, there is some 
evidence of regenerative effects of endogenously produced 
interferon-beta within the CNS.9,10
Glatiramer acetate (GA), a synthetic amino acid co-
polymer, is a small molecule that downregulates activated 
immune cells in some different fashion, but does not 
apparently affect migration across the BBB. Although the 
mechanism of action is not completely understood, it is 
felt that GA acts in the peripheral circulation by induc-
ing GA-specific T cells. There is a subsequent induction 
of regulatory CD8+ and CD4 + CD25+ T-cells in the 
  periphery. These cells then cross the BBB and re-activate 
within the CNS, resulting in downregulation of myelin-
specific immune cell activity. This in turn leads to increased 
production of anti-inflammatory cytokines and resultant 
neuroprotection. Furthermore, GA induces the production 
of neurotrophic factors, which might favor remyelination 
and axonal protection.11,12
In 2000 and 2001, mitoxantrone (Novantrone®; EMD 
Serono, OSI), a long-established chemotherapy drug, and 
interferon-beta-1a administered subcutaneously (Rebif) were 
approved to treat MS in the United States, as well as in other 
countries throughout the world.
Finally, natalizumab (Tysabri®; Biogen Idec), a monoclo-
nal antibody, was initially approved in 2004 in the United 
States and other countries. Natalizumab binds to the surface 
of all white blood cells except neutrophils and reduces their 
ability to cross the BBB and therefore there is less damage 
to CNS myelin, axons and neurons. It was removed from the 
market by the drug company in 2005 due to the discovery 
of progressive multifocal leuko-encephalopathy in two MS 
patients and one patient undergoing investigational treatment 
for Crohn’s disease. It was re-introduced into the market 
in 2006 after review of available scientific data. Since the 
re-introduction, a number of progressive multifocal leuko-
encephalopathy (PML) cases have occurred (currently about 
0.67 per 1000 exposed patients worldwide, 1.1 per 1000 
patients treated for 1 or more years, 1.59  for patients treated 
2 or more years and 0.94 for patients treated 3 or more years).   
The survival rate for PML cases is about 76%. Surviving 
patients have minimal to severe deficits (BiogenIdec website 
data, April 6, 2010).
Thus, the six drugs currently approved to treat MS fall 
into four categories: interferon-beta, GA, chemotherapy and 
monoclonal antibody. As will be discussed later, the drugs 
with higher efficacy (mitoxantrone and natalizumab) often 
have more serious potential side effects.
Now that numerous drugs are available to treat MS and 
several more are expected to be available in the next few 
years, the choice of medication for treating MS patients has 
become increasingly complicated. This article will assist 
physicians in understanding the selection process, as well 
as strategies for evaluating the efficacy of the initial drug in 
individual patients and for changing therapies if necessary. 
The evolving role of GA in the treatment of MS will be 
emphasized in this article.
MS management issues
The treatment of MS has evolved over the years, as we have 
begun to increasingly understand the disease process more 
completely, as well as the effects of the available drugs in both 
groups of patients and individual patients. This has resulted 
in improved (although not perfect) selection of disease-
modifying therapies (DMTs) for individual MS patients.
MS has been categorized into four clinical types: relaps-
ing remitting MS (RRMS), secondary progressive MS 
(SPMS), primary progressive MS (PPMS) and relapsing 
progressive MS (RPMS).
About 85% of patients initially present as RRMS. 
These patients have episodic clinical relapses (also termed 
exacerbations or attacks). Relapses are characterized by the 
development of new neurological symptoms and/or signs, 
usually progressing over hours to days, which subsequently Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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stabilize and then partially or completely resolve over 
weeks to months. Relapses may occur with greater or lesser 
frequency over time, usually thought to occur on average 
about once yearly. However, analysis of placebo-treated 
cases in recent studies has suggested that, at least earlier in 
the disease process, relapses may occur on average about 
once every 3 years.
When a patient presents with the initial clinical attack, 
this has been termed clinically isolated syndrome (CIS). 
This diagnosis generally requires an MRI scan of the brain 
and/or spinal cord, as well as blood and electrodiagnostic 
testing to rule out MS mimics. In the past, the diagnosis of 
MS required two clinical attacks. CIS is now accepted as 
being equivalent to the diagnosis of RRMS for treatment 
decision purposes.
In recent years patients have been identified as having 
possible MS based on MRI scans of the brain or spinal cord 
alone, with no suggestion of clinical events. These MRI 
scans are generally performed for reasons other than to rule 
out MS (eg, headache evaluation or cervical radiculopathy 
evaluation). When an MRI is consistent with MS, but the 
patient has no clinical symptoms related to MS, this is termed 
radiologically isolated syndrome (RIS).
Natural history studies have shown that up to about 85% 
of RRMS patients will develop SPMS over time if not treated. 
In this situation, patients demonstrate a slow progression of 
physical and/or cognitive disability not associated with clear-
cut exacerbations. In some cases of SPMS, exacerbations of 
MS are superimposed on a background of slow deterioration. 
This form of the disease is called relapsing SPMS or SPMS 
with relapses.
About 10% to 15% of patients have PPMS. In this form 
of the disease, patients develop slowly progressive neuro-
logical deterioration over time, with no obvious clinical 
relapses. Most patients develop progressive lower extremity 
weakness initially, although other symptoms may occur in 
the early stages. Over time progression continues, but no 
exacerbations occur.
Unfortunately, the clinical disease process does not 
always correlate well with MRI findings and/or patho-
logical findings. Some studies have shown several different 
pathological types of MS within the clinical RRMS type. 
Therefore, clinical MS type may not be scientifically useful 
to determine which MS medications work better in differ-
ent pathological types. At this point, we do not have any 
scientific or clinical markers to predict which medication 
may work better in individual patients. Thus, we are left with 
the scientifically unsatisfactory process of choosing initial 
therapies and subsequent therapy changes on poorly defined 
clinical and MRI markers.
Choosing initial therapies
The diagnosis of MS requires clinical acumen to evaluate 
the patient history, examination findings and MRI/blood/
urine/cerebral spinal fluid test results. No definite biological 
markers of the disease process exist. The detailed process 
of making the diagnosis of MS will not be described here, 
but at times the diagnosis cannot be reasonably certain. In 
these cases, the process of “watchful waiting” with sched-
uled examinations and periodic MRI scans of the brain with 
MS protocol (Consortium of MS Centers MRI Protocol for 
MS, 2009, mscare.org) are performed over time, often for 
several years.
However, once the diagnosis is made, treatment should 
be initiated as early as possible. Recent studies have docu-
mented the benefit of early treatment of CIS patients, begin-
ning after the first clinical attack, rather than waiting until 
a second attack occurs.13–15 As a result, interferon beta-1a 
IM, interferon-beta-1b and GA have been approved for the 
treatment of CIS.
Unfortunately, some patients are reluctant to start therapy 
after they are diagnosed with CIS and/or MS. They do not 
want to be treated with expensive therapies requiring injec-
tions and having potential significant side effects when they 
have had a single attack of MS with full recovery. They feel 
normal again and are hopeful that they will have a mild case 
of MS and can delay treatment. In these cases it is helpful to 
discuss the plan of preventing disability, even when they feel 
normal. A useful tactic includes comparisons that patients 
understand. For example, they can usually understand such 
comparisons as treating hypertension to prevent strokes and 
heart attacks, treating seizures to prevent more seizures or 
wearing a seatbelt to prevent injury in the case of an accident. 
They need to be told that it is not a good idea to wait until 
they have permanent problems before starting preventative 
treatment.
Often it is difficult to convince a patient to start treat-
ment at the same visit that the diagnosis of MS is made. 
They are often emotionally distraught by the diagnosis and 
cannot make reasonable choices about therapy at that time. 
They should be informed that treatments are available that 
can reduce disease activity and that they will need to be on 
therapy to reduce the likelihood of further attacks or progres-
sion in the future.
Patients can be referred to various websites or given the 
telephone numbers of MS organizations for more information  Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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and told to return in the near future for further discussions of 
therapy options. They should not simply be given packages 
of information and told to choose what they want to take. 
It is not reasonable for a patient newly diagnosed with MS 
to choose a therapy on their own. However, information is 
important in helping the patient and the physician to make 
the best choice. It is well known that medication will not 
help patients unless they take it. Therefore, it is important 
for patients to know what the options are in order to assure 
adherence to therapy once it is started.
When starting therapy, it is important to help them 
understand that side effects do not occur in every patient 
and that if they do occur, they often improve over time. 
Furthermore, especially with interferons, dose titration and 
prophylactic medication for flu-like syndrome is important 
to reduce side effects during initiation of therapy.16 Patients 
may be assisted in the start-up process by communication 
with other experienced MS patients, pharmaceutical company 
support programs and various MS charitable organization 
support programs. These should be offered to all patients at 
therapy initiation.
Patients mistakenly sometimes think that their initial 
choice of medication will be the only medication they can 
take indefinitely into the future. Patients should be made 
aware that each treatment has class and individual potential 
side effects and benefits, but if the initial therapy choice is 
not tolerable, other therapy can be selected. The initial choice 
is not necessarily a lifelong decision.
From the healthcare provider position, therapy choices 
are based on a balance of efficacy, tolerability and safety. 
Furthermore, as with many other fields of medicine, the prior 
experience and training of each provider will often influence 
the initial choice of medication. It is generally held that 
most providers will initiate therapy in most patients with an 
interferon or GA, as the risks of the more powerful drugs 
are too great to assume for initial therapy. However, some 
experienced physicians will choose a medication with greater 
efficacy that has a higher risk for patients who are considered 
to have a more aggressive form of MS.
The efficacy of GA and the various forms of interferons 
are felt to be similar by most physicians. Recent studies have 
shown nearly identical results on clinical and MRI parameters 
when comparing GA to interferon-beta-1a given subcutane-
ously (SQ)17 and also comparing GA to normal and double 
dose of interferon-beta-1b.18 There are some mild differences 
in MRI results between treatments, but this is variable. No 
direct comparisons of GA with interferon-beta-1a given 
intramuscularly (IM) have been undertaken. The phase III 
trials of each drug, while not directly comparable, suggest 
no overall benefit of either drug, but some smaller studies 
suggest superiority of GA.
There is some evidence that more frequent dosing of 
interferons is more effective than less frequent dosing, at 
least in the early stages of treatment,19–22 but neutralizing 
antibodies occur more often with the more frequently 
administered interferons and may affect efficacy after 18 to 
24 months of therapy. A large retrospective study of nearly 
4000 MS patients has shown no difference in interferons 
when switching from one to another.23 Other recent evidence 
has suggested that higher doses of interferons are generally 
not any more effective than the normally prescribed doses,24,25 
but higher doses of GA may or may not provide additional 
benefit.25,18
MRI results generally parallel the clinical markers of dis-
ease progression (especially if cognitive function is assessed). 
However, some recent evidence has shown less brain atrophy 
with GA, somewhat more atrophy with weekly interferon-
beta-1a IM, and even more atrophy with more frequently 
administered interferon-beta-1a and interferon-beta-1b 
subcutaneously.26 A considerable amount of literature has 
demonstrated a potential beneficial effect of GA for tissue 
repair processes as well.27
Another factor of some importance may be the potential 
of the treatment to be associated with pregnancy issues. GA 
is felt to have the least risk (package inserts for GA and all 
interferons); since many MS patients are young females of 
child-bearing age, this should be considered when choosing 
therapies.
In summary, the choice of initial therapy with a 
DMT involves an analysis of efficacy, safety and patient 
tolerability issues, as well as prescriber experience and train-
ing. There is no general consensus on initial therapy choice, 
except that it is usually GA or an interferon. Currently, GA 
is the most commonly prescribed DMT for MS both around 
the world and in the United States.28
Switching therapies – medication 
intolerance
The initial choice of DMT is often well tolerated and con-
tinues to be effective over time in many MS patients. These 
patients will continue on their initial therapy indefinitely.
However, at times the initial therapy is not optimal for 
an individual patient and a change must be made. There are 
generally two reasons for switching therapy – intolerance of 
the current therapy or ineffectiveness of the current therapy. 
Unfortunately, just as with the choice of initial therapy, there Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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are no clear-cut definitions of therapy intolerance or loss of 
efficacy.
Therapy intolerance is often influenced by individual per-
ceptions and individual tolerance to side effects. In fact, vari-
ous adjustments in therapies and treatments for side effects, 
can improve tolerability of each of the medications. Many 
articles have been written about methodologies for improving 
patient tolerance and adherence to therapy.16 Details will not 
be discussed here, but a few points will be discussed.
Injections of any sort are often difficult to tolerate. At 
times, patients have great emotional difficulty with self-
administration. Sometimes another person can be recruited to 
administer the injection. The patient sometimes experiences 
guilt about this need and counseling can be helpful. Also, 
additional nursing instructions and support may be necessary 
to continue self-injection. Of course, the necessity of taking 
medication to prevent neurological deterioration in the future 
is of utmost importance, but is often minimized by the patient 
if they are doing well neurologically. The “seat-belt analogy” 
noted earlier is often helpful in encouraging adherence.
Side effects of injections (see Table 1) are usually skin site 
injection reactions (generally with subcutaneous   injections) 
and flu-like syndrome (interferons). Various changes in injec-
tion techniques, oral medications or cutaneous medications 
may be helpful in reducing or eliminating these reactions. 
Monitoring of hepatic and hematological function also needs 
to be performed with interferons. Depression is common 
in MS patients. Therefore, psychological function of MS 
patients needs to be routinely assessed (while on any medica-
tion), but with interferons, there may be more frequent and/
or more severe depression.
When a particular therapy is deemed intolerable, then an 
alternate therapy must be chosen.
For example, when a patient is taking an interferon, 
switching to another interferon may or may not be a reason-
able strategy. Therefore, switching to fewer injections or to 
IM injections due to injection fatigue or injection site reac-
tions may be reasonable, but switching when patients have 
hepatic, hematological or psychological adverse events is not. 
Most often when side effects occur on an interferon, GA is 
considered a reasonable switch.
Interferons can induce the production of neutralizing 
antibodies in some patients, most commonly with interferon-
beta-1b, less with interferon-beta-1a SQ and least with 
interferon-beta-1a IM. Many physicians around the world 
monitor interferon neutralizing antibodies (NAbs) either 
routinely or when a patient has an exacerbation. Most, but 
not all, physicians feel that neutralizing antibodies reduce 
or eliminate the effectiveness of interferons. This is felt to 
be especially true in patients with higher titers (100 to 400 
titer or higher). When neutralizing antibodies are present 
and persist with repeat testing (usually about 3 months after 
the initial positive test), it is reasonable to switch therapies. 
However, antibodies from one interferon cross-react with the 
other interferons, so an interferon NAb positive patient who 
is going to be switched will usually be switched to GA and 
not a different interferon. It is not unreasonable to routinely 
measure interferon NAbs at 18 months after the start of 
therapy, when they have appeared in most cases, and consider 
switching to another non-interferon DMT if NAbs are present 
in higher titers (100 or greater or up to 400 or greater based 
on expert opinion).29
If a patient on GA is experiencing significant injection site 
reactions that cannot be managed with changes in injection 
technique or topical medications, then a switch to interferon 
is reasonable.
In occasional instances, if a patient needs to switch due 
to injection fatigue or inability to administer injections, 
natalizumab may be considered, even after only one drug 
“failure”. Although the risk of PML or other CNS infections 
with natalizumab is greater, the lower side effect profile, less 
frequent treatments and greater efficacy may outweigh the 
risk for individual patients.
Switching therapies – treatment 
failure
The concept of “treatment failure” based on clinical 
and/or MRI assessment is subject to individual opinions 
and expert consensus agreements. However, there is no 
consensus on assessment and measurement of treatment 
failure.30–32
Table 1 Side effect profile of glatiramer acetate and interferon-beta
Glatiramer acetate Interferon-beta
Injection-site reactions Injection-site reaction
  erythema, itching,   erythema, itching,
  swelling, pain   swelling, pain
Lipoatrophy and SQ nodules Injection-site necrosis
Immediate post-injection reaction Flu-like symptoms
Hepatotoxicity
Hematologic
toxicity
increased spasticity
Worsening of depression
Neutralizing antibodies
Modified with permission from Perumal J, Filippi M, Ford C, et al. Glatiramer acetate 
therapy for multiple sclerosis: a review. Expert Opin Drug Metab Toxicol. 2006;2:1019–
1029.36 Copyright © 2006 Taylor & Francis. Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Clinical definitions of treatment failure usually involve 
frequency and/or severity of relapses or determination of 
overall disease progression. However, even the determination 
of what constitutes a relapse and how progression should be 
measured is open to individual interpretation.
Some patients feel that if their MS symptoms do not 
resolve or if they do not return to a fully functional status, 
then this means that the medication is not working. This 
misunderstanding requires education of the patients, often 
on more than one occasion, that the benefit of treatment is 
to prevent or reduce exacerbations in the future, not to repair 
all the damage that has already occurred.
As noted above, numerous publications have attempted 
to provide a definition of treatment failure and there is no 
consensus.30–32 The following assessment is a reasonable 
attempt to describe treatment failure. It has been a com-
monly held belief, based on assessment of placebo cases in 
early MS trials, that one exacerbation annually is average 
for an untreated patient. However, in a number of more 
recent placebo-controlled trials of drug efficacy, the relapse 
rate for untreated patients was approximately one every 
3 years.33 Thus, the idea that a patient is “doing worse than 
placebo” is difficult to define. Furthermore, when looking 
at most long-term studies (5 to 12 years), it is apparent that 
many patients drop out for various reasons. However, when 
looking at the patients who remain on the study, the annual-
ized relapse rate is about 0.2 to 0.25 (one relapse every 4 to 
5 years). Therefore, a reasonable assumption may be made 
that more than one relapse in a 4- to 5-year period may be 
considered “treatment failure”. Again, there is no consensus 
on this definition of treatment failure.
The assessment of treatment failure due to disability 
progression is also fraught with difficulties. A commonly 
used measure, the Extended Disability Status Score (EDSS), 
is often used to define disease progression. A worsening 
by 0.5 to 1.0 points on the 10-point scale, sustained for at 
least 3 to 6 months, is considered a valid measure of disease 
progression. However, the scale is relatively insensitive to 
some functions, especially to fatigue, cognitive and emo-
tional functions. Since these are common impairments in 
patients with MS, other scales have been utilized. However, 
no consensus has been reached regarding which scales to use 
routinely. A recent article34 has proposed a series of tests that 
are predominantly self-administered by patients before each 
physician visit to help assess overall function.
Finally, worsening of MRI scan lesion load has been 
suggested as a measure of disease progression and treatment 
failure. However, there is no consensus on what parameters to 
utilize. Suggestions for monitoring parameters have included 
T2 lesion load, T1 lesion load, gadolinium-enhancing lesion 
load, MR spectroscopy, total brain atrophy and gray matter 
atrophy, among others.
At this point, the determination of treatment failure 
remains more of an art than a science. In the opinion of the 
author, assessment of treatment failure is performed to deter-
mine whether or not to recommend a change in medications. 
Therefore, the author uses the following criteria to determine 
whether or not to discuss change in DMT with a patient:
1.  One or more significant attacks in a 4- to 5-year period. 
The definition of a significant attack is variable. For 
example, mildly blurred vision in one eye lasting several 
days or mild tingling of the non-dominant hand last-
ing several days or a week would be considered a mild 
exacerbation. On the other hand, ataxia and hemiparesis 
requiring the new use of an ambulatory aid would be 
considered a significant attack, regardless of degree of 
recovery with or without steroids.
2.  A new T2 CNS lesion on MRI, measuring 0.5 cm or 
greater, or a new gadolinium-enhancing or T1 lesion, 
even in a clinically silent area, is considered a sign of 
significant disease activity.
3.  Progressive disability with persistent clinical alteration of 
motor, cognitive or sensory dysfunction lasting 6 months 
or longer, is considered a sign of disease progression.
If one or more of these events are detected, then there 
should be consideration of a change in DMT.
Switching therapies – which switch?
When the decision to switch is made, what DMT will be 
used? As noted above, it is reasonable to switch from an 
unsuccessful interferon to GA or vice versa. Since the inter-
ferons are somewhat similar in efficacy, a switch from one 
interferon to another due to lack of adequate efficacy does not 
seem reasonable. However, a switch from subcutaneious to 
intramuscular may be reasonable if injection site reactions or 
frequency/discomfort of injections are issues and the patient 
is doing well clinically otherwise.
Reasonable strategies are to switch from interferon to GA 
or vice versa; however, if a patient has “failed” both classes of 
therapy, then a switch to natalizumab or mitoxantrone is rea-
sonable. Mitoxantrone is currently not used very frequently 
due to the risk of cardiac muscle damage, infection or leu-
kemia, and other malignancies. Natalizumab is a reasonable 
choice and a recent publication suggests criteria for switching 
and following patients on this medication.35 This publication 
also suggests high-risk cases in which   natalizumab may be Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
335
 Glatiramer acetate for early treatment of MS
an appropriate DMT to use for initial therapy. Although 
natalizumab has a small risk of the development of PML, 
many MS patients and physicians consider the small risk 
reasonable when other therapies are failing.
Conclusions
MS is a recurrent and progressive auto-immune disease in 
which there is ongoing damage to the myelin, as well as the 
axons and nerve cell bodies, in the CNS. There is currently no 
known treatment to prevent or cure the disease, so all treatment 
is directed towards downregulation of the immune system 
within the CNS to slow the resultant tissue damage.
A number of studies have shown that starting treatment as 
soon as possible in the disease process reduces disability over 
time, so early diagnosis is imperative. Diagnosis after the first 
event is currently labeled CIS; this is considered the optimal 
time to initiate therapy. Currently in the United States, GA, 
interferon-beta-1a IM and interferon-beta-1b have received 
approval for treatment of CIS.
When choosing initial therapy in a newly diagnosed 
patient, it is most important that the patient actually adhere 
to the therapeutic regimen.16 Although patients should not 
simply be given information about all DMT drugs and told 
to choose their own therapy – they must participate in the 
decision-making process.
Generally patients are started on either GA or an inter-
feron. Efficacy of the medications is generally considered 
similar, so decisions are often made based on tolerability, 
ease of use and safety.
GA is dosed daily, so it has the most injections monthly of 
all the current DMTs. On the other hand, it has fewer systemic 
side effects, no hepatic or hematological effects and low risk 
to fetal development. The last is of considerable importance 
in MS, since many MS patients are young females of child-
bearing age. Injection site reactions are fairly common, but 
generally are of minor significance. However, at times they 
are of sufficient severity to require a change in therapy. GA 
exhibits benefit in reducing relapse rates and disability pro-
gression. Studies of GA versus interferon-beta-1a SQ and 
interferon-beta-1b show essentially the same clinical efficacy 
and similar, but not identical, MRI efficacy. GA also shows 
experimental evidence of neuro-protection/neural repair and 
less brain atrophy than interferons. Therefore, it is an excel-
lent choice for initial therapy.
Interferon-beta-1a IM is dosed least frequently of the four 
platform drugs (once weekly), but is given intramuscularly 
rather than subcutaneously. This may inhibit some patients 
who cannot self-inject intramuscular medication or obtain the 
assistance of another person. Side effects may be ameliorated 
with dose escalation and medication. Its efficacy is similar 
to that of the other therapies, although some studies have 
suggested a slower onset of action than other interferons. 
However, it is also considered an excellent choice for initial 
therapy due to its tolerability and efficacy.
Frequently administered interferons (interferon-beta-1a 
SQ and interferon-beta-1b SQ) are also reasonable choices 
for initial therapy, especially if patients desire subcutaneous 
injections that are given less frequently than Copaxone.
Uncommonly, initial therapy with natalizumab should 
be considered.
In summary, the most important factor in treating MS 
is to start early (CIS if possible) and prescribe a medication 
that the patient is likely to tolerate. If they don’t take the 
medication, it won’t work! Finally, if they are not tolerat-
ing or responding to a medication, early change to another 
therapy is recommended to prevent an increase in permanent 
MS-related disability.
Disclosure
The author has served as a speaker and advisor for Bayer, 
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